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Abstract
Background: Mesenchymal stem cells (MSCs) might act as fine-tuners of
inflammation during acute lung injury. We assessed the effects of adoptive transfer
of MSCs in acid aspiration acute lung injury and explored the role of long pentraxin
PTX3.
Methods: We conducted a prospective experimental interventional study on wild-
type (WT) and PTX3-deficient (PTX3−/−) mice. Acute lung injury was induced in WT
and PTX3−/− mice by instillation of hydrochloric acid into the right bronchus. One
hour later, animals received intraperitoneal sterile phosphate-buffered saline (PBS),
WT-MSCs (1 × 106) or PTX3−/−-MSCs (1 × 106). Twenty-four hours after injury, we
measured the effects of treatments on arterial blood gases, wet/dry lung weight (W/
D), CT scan analysis of lung collapse, neutrophils, TNFα and CXCL1 in
bronchoalveolar lavage, and plasma PTX3. D-dimer was assayed in 1 week and OH-
proline in 2 weeks to track the fibrotic evolution.
Results: In 24 h, in comparison to PBS, WT-MSCs improved oxygenation and
reduced W/D and alveolar collapse. These effects were associated with decreased
concentrations of alveolar neutrophils and cytokines. WT-MSCs increased D-dimer
concentration and decreased OH-proline levels, too.
Treatment with PTX3−/−-MSCs ameliorated oxygenation, W/D, and alveolar TNFα,
though to a lesser extent than WT-MSCs. PTX3−/−-MSCs did not improve lung
collapse, neutrophil count, CXCL1, D-dimer, and OH-proline concentrations. The
protective effects of WT-MSCs were dampened by lack of endogenous PTX3, too.
Conclusions: In acid aspiration acute lung injury, MSCs improve pulmonary function
and limit fibrosis by fine-tuning inflammation. The role of PTX3 in determining MSCs’
effects might merit further scrutiny.
Keywords: Acute respiratory distress syndrome, Acute lung injury, Stem cells,
Pentraxin 3, Acid aspiration syndrome
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Background
The incidence of the acute respiratory distress syndrome (ARDS) is elevated, and mor-
tality in recent studies still reaches 50% for the most severe form [1–5]. Moreover,
many ARDS survivors develop long-term lung fibrosis, reduced respiratory function,
and poor quality of life [1]. At onset, ARDS is characterized by severe hypoxemia and
lung edema, caused by dysregulated inflammation [1, 2]. Overstimulation of leukocytes,
cytokine storm, and altered tissue repair are key contributors to ARDS severity, mortal-
ity, and long-term morbidity [3]. However, we still lack effective pharmacological ther-
apies that fine-tune these mechanisms [4].
Mesenchymal stem cells (MSCs) are multi-potent cells derived from adult tissues
[6]. MSCs secrete multiple molecules, including anti-inflammatory cytokines,
growth factors, and anti-microbial peptides, and appear as fine-tuners of host
inflammation [6]. Previous studies showed that MSCs administration in animal
models of acute lung injury increased the ability of the host to eliminate the agent,
regulate neutrophil recruitment, and reverse altered lung permeability, without add-
itional injury [7–10]. In addition, intraperitoneal (i.p.) route for the administration
of MSCs was recently described [11]. To our knowledge, the effects of i.p. MSCs
have never been assessed in experimental acid aspiration acute lung injury [12];
moreover, the effects of MSCs on the fibrotic long-term evolution of acute lung
injury [13] have not been described, and key molecular determinants of MSCs’
effects are not fully understood.
In the present study, we tested in a mouse model of acid aspiration acute lung
injury the effects of i.p. MSCs on the early acute inflammatory reaction and on the
long-term fibrotic evolution [5, 12]. Moreover, we explored the role of pentraxin 3
(PTX3) in mediating MSCs’ effects. PTX3 is an acute-phase inflammatory mediator
produced by different cell types [3, 14] that exerts protective effects in experimen-
tal acute lung injury, closely resembling those of MSCs [15]. Previous studies indi-
cated that MSCs produce, store, and secrete PTX3 when activated [16, 17]. The
research group of Dr. G. D’Amico generated PTX3-deficient MSCs (PTX3
−/−-MSCs) [18], which showed a significant defect in promoting tissue repair in a
mice model of wound healing compared to wild-type MSCs (WT-MSCs) [18]. In
analogy, we investigated whether PTX3 deficiency in the MSCs and/or at the
endogenous level might impact the ability of MSCs to promote short- and long-
term recovery from acid aspiration acute lung injury.
The hypothesis of this study was that early treatment with MSCs in a murine model
of acid-induced lung injury might exert short- and long-term beneficial effects by
modulation of the inflammatory response and that lack of PTX3 in MSCs might reduce
their efficacy.
Methods
Ethics and permissions
Procedures involving animals and their care were conducted in conformity with the
institutional guidelines complying with national and international laws and policies.
The experimental protocol was submitted to the Italian Ministry of Health and
approved by the Animal Care Unit of the University of Milan-Bicocca, Monza, Italy.
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Isolation of MSCs
MSCs were isolated from female C57Bl/6 WT mice and from PTX3−/− mice by previ-
ously described procedures [18]. Cryopreserved aliquots of MSCs were thawed 5–7 days
before the experiments, seeded at 1000–2000 cells/cm2, and cultured at 37 °C in a 5%-
CO2 atmosphere. On early morning, MSCs were dethatched by trypsin and used fresh
for all the experiments performed that same day. Fresh MSCs at passages 5 to 7 were
used for the present study. Recent studies showed that PTX3−/−-MSCs were similar to
WT-MSCs in their ability to grow spontaneously, undergo mesengenic differentiation,
and express common MSCs’ markers [18]. As already published, PTX3−/−-MSCs dras-
tically decreased the mitogen-induced proliferation of lymphocyte in a dose-dependent
manner similarly to WT-MSCs [19]. Moreover, PTX3−/−-MSCs did not store or release
PTX3 while they tended to produce higher levels of tumor necrosis factor-stimulated
gene 6 (TSG-6) [19] compared to WT-MSCs (Additional file 1: Figure S1).
Experimental protocol
Acid aspiration acute lung injury was induced in WT- and PTX3−/−-mice as previously
described [12]. Briefly, after intubation, 1.5 ml/kg of 0.1 M hydrochloric acid was in-
stilled into the right lung, and after 10 min, the animals were extubated and placed in
an oxygenated chamber. One hour later (to reproduce possible real life clinical timing),
the mice received i.p. injection of sterile phosphate-buffered saline (PBS) or 1 × 106
WT-MSCs or 1 × 106 PTX3−/−-MSCs (all in equal volume of 200 μl).
Experimental design
Figure 1 shows the experimental design of the study in WT mice. The following mea-
sures were performed in all WT mice:
(a)Twenty-four hours after HCl instillation, the mice were sacrificed and the following
analysis were performed (detailed methods are described in Additional files):
– Arterial blood gas analysis for gas exchange
– Wet-to-dry ratio as index of edema
– Micro-CT scan to measure change over time in non-aerated lung tissue
expressed as percentage of the whole lung tissue, with more negative values
representing larger decrease of alveolar collapse;
– Histopathology examination performed according to previous study [12]
evaluating alveolar serofibrinous exudate and alveolar hemorrhage
– Bronchoalveolar lavage for differential cell count, total protein content (with
bicinchoninic acid method) and keratinocyte chemoattractant (CXCL1,
previously named KC), and tumor necrosis factor-α (TNF-α) were assayed by
ELISA
– Blood withdrawal for PTX3 levels measurement in plasma (ELISA assay)
(b)In 1 week from lung injury D-dimer (marker of fibrinolysis) [20] and matrix
metalloproteinase 13 (MMP13), an enzyme that participates in collagen degradation
[21], were detected by ELISA and by western blot in lungs lysate, respectively.
(c)Two weeks after acid-induced lung injury, the fibrotic evolution was evaluated [22].
In particular, we performed as follows:
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In PTX3−/−-mice, instead, we measured only oxygenation and wet-to-dry lung weight
ratio in 24 h and OH-Pro content in 2 weeks. Blinded researchers performed each
analysis.
Statistical analysis
Data are expressed as mean ± standard deviation if normally distributed and as median
(interquartile range) when non-normally distributed. One-way analysis of variance
(ANOVA) or Kruskal–Wallis and Dunnett’s or Dunn’s post hoc tests vs. PBS group
were used to assess differences between treatment effects in WT mice, as appropriate.
Differences in physiologic variables measured in the right vs. left lung were assessed by
t test or Mann–Whitney U test, as appropriate. p < 0.05 was considered statistically
significant.
Detailed methods can be found in the Additional file 1 of this article.
Results
Mesenchymal stem cells enhance short- and long-term recovery from experimental acid
aspiration acute lung injury
In 24 h, i.p. administration of WT-MSCs 1 h after induction of acid aspiration acute
lung injury significantly improved arterial oxygenation and decreased the alveolar–ar-
terial oxygen gradient in WT-mice in comparison to PBS (p < 0.05 and p = 0.001,
respectively) (Fig. 2a and b), without modification of PaCO2 and even in presence of
slightly worse pH values (Additional file 1: Table S1). Early improvement in oxygenation
Fig. 1 Experimental design. Experimental groups and number of animals (i.e., WT mice) studied at different
time-points (injury, treatment, and sacrifice)
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yielded by WT-MSCs was likely obtained by reduction of lung edema: in fact, the lungs’ wet-
to-dry ratio in 24 h was decreased by WT-MSCs in comparison to PBS (P < 0.05) (Fig. 2e).
Similarly, micro-CT scan analysis showed that the extent of lung collapse significantly de-
creased between 1 and 24 h in WT mice treated by WT-MSCs (p= 0.01), likely indicating
decreased superimposed weight from reduced lung edema (Table 1 and Fig. 3), but not in
those treated by PBS. Histology performed in 24 h showed decreased disruption of lung
structures in mice treated by WT-MSCs in comparison to PBS (Table 1), even though this
difference did not reach statistical significance. BAL total protein concentrations were left un-
changed by WT-MSCs treatment (Fig. 2f). Mice treated by WT-MSCs, indeed, showed sig-
nificant reduction of total cell count in BAL fluid in 24 h and substantial dampening of
neutrophil recruitment into the alveoli (p < 0.05 for both; Fig. 2c, d) in comparison to PBS.
Accordingly, levels of proinflammatory cytokines (i.e., CXCL1 and TNF-α) in BAL fluid were
significantly reduced by WT-MSCs (p < 0.05 and p < 0.01, respectively), but not by PBS
(Table 1). Interestingly, circulating PTX3 was reduced in WT-mice treated by WT-MSCs (al-
beit non-significantly) and not in WT-mice treated by PTX3-deficient MSCs (Table 1).
Fig. 2 Early effects of mesenchymal stem cells (MSCs) on oxygenation, lung edema, and alveolar
inflammatory cells in acid aspiration acute lung injury. Wild-type MSCs ameliorated arterial oxygen tension
(a) and alveolar–arterial oxygen gradient (b) in experimental model of acid aspiration lung injury in 24 h, as
well as PTX3-deficient MSCs, albeit to a lesser extent (Kruskal–Wallis p < 0.05 [A] and p = 0.001 [B]; Dunn’s
post hoc *p < 0.05 and **p < 0.01 vs. PBS. PBS n = 21; WT-MSCs n = 28; PTX3−/−-MSCs n = 11). Total cell count
(c) and total neutrophil (PMN) count (d) in the broncho-alveolar lavage (BAL) were decreased by WT-MSCs
but not by PTX3−/−-MSCs in experimental groups in 24 h (Kruskal–Wallis p < 0.05 [C] and p = 0.01 [D]; Dunn’s
post hoc *p < 0.05 and **p < 0.01 vs. PBS. PBS n = 21; WT-MSCs n = 17; PTX3−/−-MSCs n = 9). WT-MSCs signifi-
cantly reduced lung edema (c), as measured by wet-to-dry lung weight ratio (wet/dry) in the experimental
groups in 24 h (ANOVA p < 0.05 [e]; *Dunnett’s post hoc p < 0.05 vs. PBS. PBS n = 21; WT-MSCs n = 18; PTX3
−/−-MSCs n = 10). No difference was seen in BAL total protein concentrations (f) (PBS n = 22; WT-MSCs n =
20; PTX3−/−-MSCs n = 10). (PBS = acid aspiration acute lung injury + intraperitoneal (i.p.) PBS treatment in 1 h;
WT-MSCs = acid aspiration acute lung injury + i.p. wild-type MSCs treatment in 1 h; PTX3−/−-MSCs = acid
aspiration acute lung injury + i.p. PTX3-deficient MSCs treatment in 1 h)
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In this study, we showed that treatment by i.p. WT-MSCs administered 1 h after acid
aspiration attenuated the evolution of fibrosis, as demonstrated by lower collagen
deposition (OH-Pro assay) in 2 weeks (Fig. 4a) in comparison to mice treated by PBS.
In 1 week, D-dimer concentration was significantly increased in the lungs of mice
treated with WT-MSCs (p < 0.001, Fig. 4b) in comparison to PBS, suggesting that
dampening of long-term fibrotic evolution might have followed both reduced inflam-
mation and enhanced fibrinolysis by WT-MSCs in the days after injury.
Systemic deployment of WT-MSCs in 24 h
In an effort to evaluate whether i.p. WT-MSCs migrate systemically in mice with acid as-
piration acute lung injury, we performed western blot analysis to detect GFP+ WT-MSCs
presence in the lungs, spleen, liver, and peritoneal lavage in 24 h. Additional file 1: Figure
S3 shows actual blots with no apparent signal of GFP+ WT-MSCs presence in the lungs,
spleen, and liver as opposed to positive controls. In the peritoneal lavage, instead, WT-
MSCs were still present in 24 h but by lower intensity, probably because, as previously
shown [23], they formed aggregates and adhered to the peritoneal cavity walls.
Fig. 3 Short-term effects of MSCs: CT scan images. Chest CT images from representative study animals
treated by PBS, WT-MSCs, or PTX3−/−-MSCs in 1 h after HCl instillation and 24 h showing reduced radiologic
signs of lung edema and collapse, especially in the right lung
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Lack of PTX3 in MSCs reduces early and long-term protection from acid aspiration acute
lung injury
PTX3−/−-MSCs were isolated from the bone marrow of PTX3-knockout mice. The
extensive characterization of PTX3−/−-MSCs demonstrated that these cells did not
seem to modify their in vitro phenotypical and functional properties [18] (Additional
file 1: Figure S1). In 24 h, treatment by PTX3−/−-MSCs ameliorated oxygenation only
to a lesser extent than WT-MSCs (Fig. 2). Reduced short-term effects on oxygenation
in comparison to WT-MSCs were paralleled by less effective reduction of wet-to-dry
lung weight ratio by PTX3−/−-MSCs (Fig. 2a, b, e) and the absence of effects of PTX3-
deficient cells on radiological signs of regional lung collapse and edema (Table 1). Hist-
ology found reduction of lung injury, albeit non-significant (Table 1). In summary,
PTX3−/−-MSCs seemed less effective than WT-MSCs in limiting formation of lung
edema in 24 h after acid aspiration. At variance from WT-MSCs, treatment with PTX3
−/−-MSCs did not reduce total cell and neutrophil count (Fig. 2) as well as CXCL1
levels in the alveolar space (Table 1). Thus, the more limited effectiveness of PTX3
−/−-MSCs in enhancing lung recovery after acid aspiration acute lung injury might have
been related to ineffective reduction of the acute inflammatory processes. Moreover,
PTX3−/−-MSCs could not modulate fibrinolysis in the days following injury nor impact
the long-term fibrotic evolution, as demonstrated by unchanged levels of D-dimer and
OH-proline in comparison to PBS (Fig. 4a, b). However, WT- and PTX3−/−-MSCs did
not seem to modulate activity of MMP13 in 1 week (Additional file 1: Figure S2) to
impact remodeling and fibrosis.
Effects of study treatments on PTX3 knockout mice with acid aspiration acute lung injury
Extent of lung injury was similar between WT and PTX3−/− mice (t test in 24 h in WT-
mice + PBS vs. PTX3−/−-mice + PBS: PaO2, p = 0.151; wet-to-dry lung weight, p =
0.099). When administered to PTX3−/−-mice: WT-MSCs improved lung function and
reduced fibrosis, but the difference with PBS was non-significant (Additional file 1:
Table S3); PTX3−/−-MSCs induced a further non-significant reduction of the alveolar–
arterial gradient and of wet-to-dry lung weight ratio, while PaO2 and fibrosis worsened
Fig. 4 Effects of WT-MSCs on the fibrotic evolution of acid aspiration acute lung injury. Collagen deposition
(OH-proline assay) (a) in lung tissue in the experimental groups in 2 weeks: WT-MSCs decreased presence
of fibrotic tissue while PTX3−/−-MSCs could not (ANOVA p < 0.05 [A]; *Dunnett’s post hoc p < 0.05 vs. PBS.
PBS n = 16; WT-MSCs n = 12; PTX3−/−-MSCs n = 10)). Decreased fibrotic evolution by WT-MSCs was likely
mediated by improved fibrinolysis (b) in the lungs over the days following acid aspiration acute lung injury
(ANOVA p < 0.01 [B]; *Dunnett’s post hoc p < 0.05 vs. PBS. PBS n = 5; WT-MSCs n = 5; PTX3−/−-MSCs n = 6)
(PBS = acid aspiration acute lung injury + intraperitoneal (i.p.) PBS treatment in 1 h; WT-MSCs = acid
aspiration acute lung injury + i.p. wild-type MSCs treatment in 1 h; PTX3−/−-MSCs = acid aspiration
acute lung injury + i.p. PTX3-deficient MSCs treatment in 1 h)
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in comparison to WT-MSCs (Additional file 1: Table S3). Thus, endogenous PTX3
might collaborate in the protective effects of WT-MSCs from fibrosis, while it might
limit their effectiveness in reducing lung edema.
More results are provided in the Additional files of this article.
Discussion
Study’s main findings can be summarized as follows: WT-MSCs dampen short- and
long-term sequelae of acid aspiration acute lung injury in mice in terms of improved
oxygenation, reduced edema causing lung collapse, and reduced fibrotic evolution,
likely by fine-tuning the acute inflammatory reaction and the subsequent fibrinolysis
and tissue repair process; moreover, lack of PTX3 gene in MSCs and in the injured host
might reduce the beneficial effects of MSCs.
In the present study, we administered i.p. WT-MSCs 1 h after intratracheal instilla-
tion of hydrochloric acid, potentially reproducing real-life treatment of ARDS caused
by aspiration of gastric contents [1, 12], one of the major direct causes of ARDS [24,
25] with a mortality rate around 35–40% and significant long-term fibrosis [1]. In 24 h
from injury, we could show multiple short-term beneficial effects of WT-MSCs: as
previously shown [7, 26], MSCs seemed to reduce the early inflammatory reaction in
the lungs and to avoid excessive response and additional damage. In our study, indeed,
MSCs dampened leukocyte trafficking through the alveolar–epithelial barrier as well as
their activation and release of primary inflammatory cytokines. In turn, as testified by
oxygenation, wet-to-dry and CT scan data, this led to decreased accumulation and/or
improved clearance of lung edema and inflammatory cells in the alveolar and third-
space compartments and to attenuated extent of alveolar collapse. However, histology
did not improve after WT-MSCs administration, maybe due to insufficient numerosity;
similarly, protein content in BAL was not reduced by MSCs, but this could have
followed direct extravasation after acid-induced physical disruption of the alveolar–epi-
thelial integrity. In our model, both lungs showed physiologic alterations, thus indicat-
ing that the left lung could completely compensate for the ventilation needs of the
animals (Additional file 1: Table S2) [27].
In 2 weeks from acute lung injury onset, we also showed decreased long-term colla-
gen deposition in the lungs associated with treatment by WT-MSCs. Moreover, the
long-term reduction of fibrosis was preceded by increased fibrinolysis in 1 week. Our
data, in keeping with recent literature [7, 9, 20], seem to suggest that the beneficial ef-
fects of MSCs on the fibrotic evolution of acute lung injury might include reduction of
the acute-phase inflammatory reaction and reduced fibrosis in 2 weeks. Moreover,
decreased respiratory effort during the early phases induced by improved gas exchange
could have reduced interstitial lung edema [28] and the risk of additional ventilation-
induced lung injury (VILI) and fibrosis [13]. In summary, it would be tempting to say
that ours and the previous data indicate that MSCs might be regarded as personalized
modular therapies limiting short- and long-term acute lung injury severity by fine-
tuning inflammation and tissue remodeling. However, to date, whether these hypoth-
eses hold true and will translate in improved mortality and long-term quality of life in
human ARDS remains to be determined.
PTX3 is a marker of severity in human ARDS [29], and experimental models showed
that PTX3 is as key determinant of the evolution, morbidity, and mortality of acute
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lung injury [30, 31]. A recent study by Cappuzzello and colleagues showed that while
WT-MSCs improved tissue repair in experimental wound healing, PTX3−/−-MSCs
could not [18]. Similarly, we showed that the early dampening of leukocyte migration
and release of pro-inflammatory cytokines in the injured lungs by WT-MSCs could not
be replicated when PTX3−/−-MSCs were adopted. This likely led to poorer effects on
oxygenation and wet/dry ratios and no improvement in the CT scan analysis of lung
collapse as well as no decrease in inflammatory cells and acute-phase primary cytokines
in the BAL. The positive effect of PTX3−/−-MSCs treatment on the TNF-α levels may
depend on the anti-inflammatory role of TSG6 [32, 33], which is highly expressed in
PTX3−/−-MSC (Additional file 1: Figure S1). Previous studies in a mice model of
bilateral acid aspiration lung injury showed that interaction between PTX3 and P-
selectin is crucial for regulation of leukocyte recruitment with consequences on
cytokine production and lung injury [23], and similar mechanisms might underlie lack
of lung protection by PTX3−/−-MSCs. Moreover, we described that long-term fibrinoly-
sis and subsequent fibrotic evolution could not be prevented by PTX3−/−-MSCs,
possibly suggesting PTX3-mediated enhancement of lung tissue repair by WT-MSCs
[18, 20]. On the other hand, our data indicate that the beneficial effects exerted by
WT-MSCs are associated with a reduction in plasma PTX3, as if improvement of lung
injury preceded modification of endogenous PTX3 production. However, lack of
endogenous PTX3 seemed to reduce WT-MSCs effects (Additional file 1: Table S3),
maybe by impairment of local cell-to-cell interaction. Our results do not generate a
clear hypothesis on the role of PTX3 as molecular determinant of the lung protection
exerted by MSCs, and further studies are warranted, maybe exploring other etiologies
and time-points.
In our study, we could not detect presence of WT-MSCs in the liver, spleen, or lungs
in 24 h, while in keeping with previous findings [34], a signal was still present in peri-
toneal lavage (Additional file 1: Figure S3). On the other hand, since levels of circulat-
ing PTX3 were lower and lung fibrinolysis was increased after administration of WT-
MSCs, we might speculate possible migration and direct effect of MSCs at the site of
injury but this cannot be concluded with any confidence. In summary, our data are not
definitive to elucidate whether i.p. WT-MSCs act through paracrine vs. direct
mechanisms.
This study suffers by a number of relevant limitations: as most of the measures
required sacrifice of the animals (e.g., BAL), we could not assess in the same animal all
the effects at different time-points but each effect was assessed in a subset of animals
receiving the same injury and therapy, which might have introduced some heterogen-
eity. We only examined three time-points (i.e., 24 h and 1 and 2 weeks), which might
have prevented us from description of other effects of WT-MSCs or PTX3−/−-MSCs in
acid aspiration acute lung injury. Apart from resources limitation, our choice was based
on previous observations on the time-course of the studied animal model [12]. We
described reduced effectiveness of WT-MSCs induced by lack of PTX3 only in a mur-
ine model of non-infective acid aspiration lung injury and translation of these findings
to other etiologies (e.g., infective pulmonary ARDS) and/or to the clinical setting war-
rants extreme caution. While we could determine significant effects of PTX3 presence
in MSCs in 1 week to modulate fibrosis, the downstream effects of PTX3 presence in
MSCs during the early acute phase (e.g., modulation of leukocyte recruitment by
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binding with P-selectin) remains to be elucidated. We did not evaluate the alteration of
the alveolar–capillary permeability from a more molecular point of view (such as ex-
pression of tight or adherent junction proteins), but only by measuring the lung edema
following such alterations (wet-to-dry ratio and the CT scan analysis). Besides the
standard histological analysis, we did not perform more quantitative approach using
stereological assessment of the tissue injury, and this might have limited our possibil-
ities to describe more significant differences. This is a preliminary study: the small
number of mice used and lack of other administration routes could have reduced sig-
nificant differences. The experiments on PTX3−/− mice were subsequent and separate
from those on WT mice. Finally, volume of fluid instilled i.p. (i.e., 200 μl) might have
induced cardiovascular impairment favoring pulmonary edema.
Conclusions
The results presented here suggest that i.p. adoptive transfer of MSCs enhances short-
and long-term lung recovery when cells are administered 1 h after onset of acute lung
injury. PTX3, an acute-phase inflammatory mediator, might play a role in the lung pro-
tection exerted by MSCs, in particular against fibrosis, but this needs further clarifica-
tion. Studies on the molecular mechanisms of actions of MSCs as well as on the risks
associated with their administration should still proceed in parallel with ongoing trans-
lational studies [35]. In particular, PTX3 genetic polymorphisms have been associated
with risk of microbial infections [36–38], and it will be important to assess whether
PTX3 polymorphisms are associated with outcome in ARDS and in clinical trials aimed
to assess the potential of MSCs.
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